Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
NCT ID: NCT06094842
Last Updated: 2025-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2025-04-15
2028-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04253483
Proton Radiation Therapy in Treating Patients With Prostate Cancer
NCT01045226
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
NCT05691465
Study of HPN424 in Patients With Advanced Prostate Cancer
NCT03577028
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
NCT03649841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for T cell product manufacturing and may undergo bridging therapy at the discretion of the treating clinician on study. Patients then undergo lymphodepleting chemotherapy with cyclophosphamide intravenously (IV) and fludarabine IV on days -5, -4 and -33 or single agent bendamustine on days -4 and -3 at the discretion of the treating clinician and/or principal investigator (PI). Patients receive an autologous L1CAM-specific CAR+EGFRt+ T cell infusion on day 0. Based on disease response and persistence of CAR T cells, patients may receive additional lymphodepletion chemotherapy and an autologous L1CAM-specific CAR+EGFRt+ T cell infusion as soon as 6 weeks and no later than 24 weeks after the first infusion, or at the discretion of the PI. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients undergo x-ray imaging, computed tomography (CT), bone scan, and blood sample collection throughout the trial. Additionally, patients may undergo tissue biopsy on the trial.
After completion of study treatment, patients are followed up monthly for 3 months, then every 3 months up to 12 months then may undergo long-term follow-up annually for up to 15 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (autologous L1CAM-specific CAR+EGFRt+ T cells)
Patients undergo leukapheresis to obtain PBMCs for T cell product manufacturing and may undergo bridging therapy at the discretion of the treating clinician on study. Patients then undergo lymphodepleting chemotherapy with cyclophosphamide IV and fludarabine IV on days -5, -4 and -33 or single agent bendamustine on days -4 and -3 at the discretion of the treating clinician and/or PI. Patients receive an autologous L1CAM-specific CAR+EGFRt+ T cells infusion on day 0. Based on disease response and persistence of CAR T cells, patients may receive additional lymphodepletion chemotherapy and an autologous L1CAM-specific CAR+EGFRt+ T cell infusion as soon as 6 weeks and no later than 24 weeks after the first infusion, or at the discretion of the PI. Patients also undergo ECHO or MUGA during screening. Patients undergo x-ray imaging, CT, bone scan, and blood sample collection throughout the trial. Additionally, patients may undergo tissue biopsy on the trial.
Bendamustine
Given IV
Biopsy
Undergo tissue biopsy
Biospecimen Collection
Undergo blood sample collection
Bone Scan
Undergo bone scan
Bridge Therapy
Undergo bridging therapy
Computed Tomography
Undergo CT
Cyclophosphamide
Given IV
Echocardiography
Undergo ECHO
Fludarabine
Given IV
Leukapheresis
Undergo leukapheresis
Multigated Acquisition Scan
Undergo MUGA
T-cell Receptor-engineered T-cells
Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
X-Ray Imaging
Undergo chest x-ray
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bendamustine
Given IV
Biopsy
Undergo tissue biopsy
Biospecimen Collection
Undergo blood sample collection
Bone Scan
Undergo bone scan
Bridge Therapy
Undergo bridging therapy
Computed Tomography
Undergo CT
Cyclophosphamide
Given IV
Echocardiography
Undergo ECHO
Fludarabine
Given IV
Leukapheresis
Undergo leukapheresis
Multigated Acquisition Scan
Undergo MUGA
T-cell Receptor-engineered T-cells
Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
X-Ray Imaging
Undergo chest x-ray
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to understand and give written informed consent
* Confirmation of small cell neuroendocrine prostate cancer (SCNPC) diagnosis by internal pathology review of initial or subsequent biopsy or other pathologic material at Fred Hutchinson Cancer Center/University of Washington
* Previously treated with a platinum-based chemotherapy regimen for SCNPC
* Participants may not have received prior therapy or plan to receive therapy (chemotherapy, immunotherapy and/or radiation therapy) or have undergone or plan to undergo major surgery within the last 3 weeks prior to leukapheresis AND initiation of lymphodepleting chemotherapy. Participants who have developed SCNPC in the context of prior androgen deprivation therapy (ADT) (i.e. medical/surgical castration) may continue on ADT at the discretion of their treating provider
* Evidence of L1CAM positivity by immunohistochemistry review of the patient's archival/fresh tumor samples
* Metastatic or locally advanced and unresectable disease
* Adequate performance status (Eastern Cooperative Oncology Group \[ECOG\] 0 or 1)
* Expected survival \> 3 months
* Fertile participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the CAR T cell infusion
* Measurable disease per RECIST v1.1 criteria as determined by CT, MRI or positron emission tomography (PET) scan
* Hemoglobin \> 9 g/dL (prior to leukapheresis)
* Absolute neutrophil count (ANC) \> 1,500 per mm\^3 (prior to leukapheresis)
* Platelets \> 100,000 per mm\^3 (prior to leukapheresis)
* Creatinine ≤ 1.5 x upper limit of normal (ULN) (prior to leukapheresis)
* Bilirubin ≤ 1.5 x ULN (≤ 3 x ULN in patients with known Gilbert's syndrome) (prior to leukapheresis)
* Aspartate transaminase (AST) ≤ 3.0 x ULN (prior to leukapheresis)
* Alanine transaminase (ALT) ≤ 3.0 x ULN (prior to leukapheresis)
* Alkaline phosphatase ≤ 3.0 x ULN (prior to leukapheresis)
* All prior treatment related toxicity prior to leukapheresis ≤ grade 2 by National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version (v) 5.0
Exclusion Criteria
* Participants with active human immunodeficiency virus (HIV) (testing not required per protocol but status noted). Participants with adequately treated HIV will be permitted to enroll. Adequately treated HIV will be defined as being on a stable regimen of highly active anti-retroviral therapy (HAART), CD4 count ≥ 350 cells/mcL, undetectable viral load on standard polymerase chain reaction (PCR)-based testing and not requiring antibiotics or antifungal agents for the prevention of opportunistic infections
* Participants with active hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as HCV RNA is detected) infection. Participants with prior hepatitis B virus (HBV) infection are eligible. Participants with a history of hepatitis C virus (HCV) infection are eligible if they have been treated with curative intent and their hepatitis C PCR viral load is negative
* Known history of unstable angina or myocardial infarction (MI) within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy
* New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), clinically significant hypotension, uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of \< 35%
* Known history of clinically significant active chronic obstructive pulmonary disease (COPD), or other moderate-to-severe chronic respiratory illness present within 6 months
* Participants with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing. Those with an forced expiratory volume (FEV1) of \< 50 % of predicted or diffusing capacity for carbon monoxide (DLCO) (corrected) \< 40% will be excluded. Patients with \> grade 1 dyspnea at rest or oxygen saturation \< 94% on room air (resting)
* Infection requiring intravenous antibiotic use within 2 weeks of leukapheresis or uncontrolled active infection
* Baseline serum sodium level \< 130 mEq/L
* Research participant is not receiving systemically administered steroid therapy. Physiologic glucocorticoid replacement therapy for management of adrenal insufficiency is allowed (≤ 10 mg daily of prednisone or equivalent)
* History of an autoimmune disease requiring immunosuppressant therapy within the past 5 years
* Other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
* Known history of brain metastases.
* Note: Brain imaging is not required to determine eligibility. However, this should be performed if there is clinical suspicion for brain metastases
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Schweizer
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2023-07464
Identifier Type: REGISTRY
Identifier Source: secondary_id
FH20229
Identifier Type: OTHER
Identifier Source: secondary_id
RG1123589
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.